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High-protein induced renal enlargement is growth hormone ing uninephrectomy [4], renal growth following strepto-
independent. zotocin-induced diabetes [5], potassium depletion [6] and
Background. Growth hormone (GH) and insulin-like growth high-protein (HP) diets [7].factors (IGFs) have been postulated as pathogenic factors in
Insulin-like growth factor-I is a prime candidate forseveral forms of renal growth, including that induced by high-
the mediation of renal growth. Rats infused with IGF-Iprotein (HP) diets. Compensatory renal growth (CRG) follow-
ing renal uninephrectomy is strictly GH dependent, while the [8] and IGF-I transgenic mice [9] both display glomerular
exact role of GH as a regulating factor in HP induced renal hypertrophy in the setting of high circulating IGF-I lev-
growth has not been fully clarified. els. In addition, low protein containing (LP) diets haveMethods. To elucidate a possible direct role for GH in HP-
shown to lower circulating IGF-I levels [10] whereasinduced renal growth, we examined the effect of a newly devel-
IGF-I was found to be elevated in rats fed a HP dietoped specific GH-receptor (GHR) antagonist (B2036-PEG)
on renal growth and renal GH/IGF-system expression in HP- and displaying renal hypertrophy [7, 11].
fed mice. The precise involvement of GH in protein-induced
Results. Mice fed a HP diet (45% protein) for one week
hypertrophy is, at present, unclear. In GH-deficientdemonstrated renal hypertrophy and increased renal IGF-I.
Lewis dwarf rats, renal IGF-I levels and renal growthGH receptor antagonist (GHRA) treatment neither modified
renal IGF-I nor abolished the renal hypertrophy. In contrast, were unaffected by HP diets [12], suggesting that the
however, GHRA administration did modify renal mRNA ex- renal growth is GH-dependent. In contrast, however,
pression of many members of the GH and IGF systems. Chin and Bondy demonstrated that HP in GH-deficientConclusions. The major new finding is that HP-induced re-
rats, displaying a 90% reduction in GH levels, increasednal growth in adult mice is GH independent.
renal IGF-I and induced renal hypertrophy, suggesting
a GH-independent renal growth [7].
Recently, a series of highly specific GH receptorInsulin-like growth factor (IGF) I has pleiotropic ef-
(GHR) antagonists (GHRAs) has been developed forfects on metabolism, cellular proliferation and differenti-
potential therapeutic use [13–15]. These GHR antago-ation that is produced under the influence of growth
nists have proven to be effective in inhibiting renal en-hormone (GH) [1]. IGF-I is a member of the IGF system
largement in diabetic mice [14, 16] and in CRG afterthat also consists of IGF-II, 2 types of IGF receptors
uninephrectomy [4]. In the present study, we investigatedand six different IGF binding proteins (IGFBPs) [2]. In
the involvement of GH in HP-induced renal growth us-addition, nine IGFBP related proteins have been de-
ing a novel GHRA (B2036-PEG). The effects of HP dietscribed [3].
alone and with GHRA administration were investigatedGrowth hormone and the IGFs have been implicated
with a focus on the renal growth and the circulatory,as renotropic factors in several forms of renal enlarge-
ment such as compensatory renal growth (CRG) follow- hepatic and renal expression of the GH and IGF system.
Key words: growth hormone, insulin-like growth factor, high protein METHODS
diet, kidney, liver, mouse, mRNA.
Animals
Received for publication August 15, 2000
Adult female Balb/C(a) mice with initial body weightsand in revised form April 5, 2002
Accepted for publication May 24, 2002 of 17 to 18 g (Bomholtgaard, Ry, Denmark) were used
in the study. The animals were housed 8 per cage on 2002 by the International Society of Nephrology
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white special spanwall bedding. Mice had free access to Blood glucose and serum insulin
water and were kept at a constant temperature (21  Blood glucose was measured in unanesthetized ani-
1C), humidity (55  5%) and a 12-hour light, 12-hour mals in tail vein blood by a Haemoglucotest 1-44 and
dark cycle (07.00 to 19.00 light). The study complied Reflolux II reflectance meter (Boehringer-Mannheim,
with Danish regulations for care and use of laboratory Mannheim, Germany). Serum insulin was measured by
animals. an ultrasensitive rat insulin enzyme-linked immunosor-
bent assay (ELISA) from DRG Instruments GmbH
Study design (Marburg, Germany). Semilog linearity of mouse serum
and rat insulin was found at multiple dilutions, indicatingThe mice were randomly allocated into three groups
antigen similarity between mouse and rat insulin. Theof 16 animals. Eight animals per group were sacrificed
intra-assay and inter-assay coefficients of variation (CV)at day 2 (d2), and 8 at day 7 (d7). Animals from group 1
were 5% and 10%, respectively.[normal-protein (NP) group] were fed a specific synthetic
diet containing 18% protein (custom made; Altromin,
Serum IGF-I and kidney IGF-I determinationsLage, Germany). Animals from group 2 [high-protein
Serum IGF-I was measured after extraction using acid-(HP) group] were fed an isocaloric specific synthetic diet
ethanol. The intra-assay and inter-assay CV were 5%containing 45% protein (custom made, Altromin) and
and 10%, respectively. Tissue extraction of renal IGF-Iinjected with 0.154 mol/L NaCl, the vehicle for the other
was performed according to D’Ercole, Stiles and Un-treatment. Animals from group 3 (HP/GHRA group)
derwood [19], and corrected for the contribution of en-were fed an isocaloric-specific synthetic diet containing
trapped serum IGF-I [20].45% protein and injected with 2.5 mg/kg human GHRA
B2036-PEG at d0, d1, d2, d4, and d6. The rationale for Serum and kidney IGFBPs
the dose follows that of previous studies [4, 14, 16, 17].
Sodium dodecyl sulfate-polyacrylamide gel electro-
In a second experiment, designed to validate the effec- phoresis (SDS-PAGE) and Western ligand blotting
tiveness of the GHRA dose used in inhibiting the GH- (WLB) analysis were executed according to the method
receptor, 32 mice were randomly allocated to four groups of Hossenlopp et al [21] as described previously [22].
of eight animals. Group 1 duplicated the treatment of
the NP group as described earlier; group 2, duplicated Gene-expression of IGF system genes (mRNA)
in tissuesthe HP group; group 3 were HP 2.5 mg/kg/2 d GHRA
injected, as the HP/GHRA group described earlier; Northern analysis. Gene-expression was measured by
group 4 animals were fed an isocaloric-specific synthetic Northern blot analysis. Total RNA was extracted from
diet containing 45% protein and injected with 20 mg/kg kidney and liver samples by the guanidinium thiocyanate
human GHRA B2036-PEG at d0, d1, d2, d4, and d6, method [23]. RNA samples were electrophoresed in 1%
agarose gels and transferred to nylon membranes (Hy-and were designated the HP/8GHRA group.
bond N; Amersham, ’s Hertogenbosch, The Nether-The GHRA (B2036-PEG) was kindly provided by
lands). Filters were hybridized with 32P-labeled cDNASensus Drug Development Corporation (Austin, Texas,
fragments encoding for each of the six mouse IGFBPsUSA) [15], dissolved in 0.154 mol/L NaCl and injected
[24], mouse acid labile subunit (ALS; kindly providedSC in a volume of 0.5 mL. The molecule has a modifica-
by Dr. Y.R. Boisclair, Department of Animal Sciences,tion in the first GHR binding site resulting in a 30 to 50
Cornell University, Ithaca, NY, USA), mouse IGF-Itimes increased affinity for the human GHR. In addition,
and -II (kindly provided by Dr. G.I. Bell, Howardin the second GHR binding site, amino acid 120 is modi-
Hughes Institute, Chicago, IL, USA), rat IGF-I receptorfied preventing GHR dimerization. GHRA was provided
(kindly provided by Dr. H. Werner and Dr. D. LeRoith,in a pegylated formula to warrant prolonged biological
National Institutes of Health, Bethesda, MD, USA),
action of the molecule [18].
GHR/GHBP [25] and glyceraldehyde-3-phosphate de-
Animals were weighed and their food consumption hydrogenase (GAPDH) at 65C according to the method
and blood glucose were determined at days 0, 2 and 7. of Church and Gilbert [26].
Before they were sacrificed, the animals were anesthe-
tized with pentobarbital (50 mg/kg IP) and non-fasting Real-time PCR
blood samples were collected exactly five minutes later cDNA synthesis. The RNA preparation was treated
from the retrobulbar plexus through heparinized capil- with 0.5 units of DNAse I (Invitrogen, Breda, The Neth-
lary tubes under light ether anesthesia. The serum sam- erlands) per g total RNA for 15 minutes at room tem-
ples were kept at –80C for later analysis. Whole liver perature. The reaction was terminated by addition of 1L
and the left kidney were removed and snap frozen in of 25 mmol/L ethylenediaminetetraacetic acid (EDTA),
followed by heating for 10 minutes at 65C, after whichliquid nitrogen.
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it was placed on ice. This mixture was used for reverse
transcription. cDNA was synthesized by incubation of 1g
of total RNA with 1.25 L of a mixture of oligo(dT)18
primers (400 nmol/L)/random hexamers (50 mol/L) in
a total volume of 15L for five minutes at 70C, followed
by immediate incubation on ice. To this mixture 5 L
of 5 reverse transcription (RT) buffer, 0.5 L of 10
mmol · L-1 dNTP mix, 1 L of M-MLV reverse tran-
scriptase (200 U/L; Promega) and water was added to
an end volume of 25 L. The cDNA synthesis reaction
was allowed to proceed for 45 minutes at 37C, followed
by a 15-minute incubation at 42C. The enzyme was Fig. 1. Kidney weights of mice receiving a normal protein fodder (),
inactivated by heating at 95C for five minutes. high-protein fodder ( ) and high-protein fodderGHRA B2036-PEG
( ) for 2 and 7 days. Values are means  SEM (N  8). *P  0.001,Determination of mRNA levels. mRNA levels were
statistical significance level between the indicated group and the respec-quantitatively determined on an ABI Prism 7700 Se- tive control.
quence Detection system (Applied Biosystems, Foster
City, CA, USA) using SYBR-green technology. Poly-
merase chain reaction (PCR) primers for mouse IGF-I Statistical analysis
(mIGF-I) and mouse hypoxanthine phosphoribosyltrans-
Data were examined for distribution, variance homo-ferase (mHPRT) (household gene) were designed using
geneity (F-test) and analyzed using the Student unpairedPrimer Express 1.5 Software with the manufacturer’s de-
t test if appropriate. Otherwise, the significance of differ-fault settings. The primers used for mHPRT were: forward
ence was compared by one-way analysis of variance fol-primer, TTGCTCGAGATGTCATGAAGGA; reverse
lowed by pair-wise comparisons with the LSD method.primer, AGCAGGTCAGCAAAGAACTTATAG, re-
All data are expressed as mean SEM, with N indicatingsulting in an amplicon size of 90 base pairs.
the number of mice studied; P values equal to or lessThe primer set used for mIGF-I were: forward primer,
than 5% are considered significant.CCACACTGACATGCCCAAGAC; reverse primer,
CCTTCTCCTTTGCAGCTTCGT resulting in an ampli-
con size of 75 base pairs. In 96-well plates, 12.5 L RESULTS
SYBR-green master mix was added to 12.5 L of cDNA Body weight, food consumption, blood glucose and
(2% of the amount of cDNA derived from a reaction serum insulin
with 1.0 g of RNA) and 300 nmol/L of forward and
The body weights of the different study groups werereverse primers in water. Plates were heated for two
measured at the beginning (d0) and the end (d2 or d7)minutes at 50C and 10 minutes at 95C. Subsequently,
of the experimental period. The mean body weight at40 PCR cycles consisting of 15 seconds at 95C and 60
day 0 was 18.2  0.3 g with no significant differencesseconds at 60C were applied. The absence of genomic
between the groups. At d2 and d7, the mean bodyDNA contamination in the RNA preparations was con-
weights of the different groups were not significantlyfirmed by running RNA samples that had not been sub-
changed by any of the treatments (data not shown). Foodjected to reverse transcription.
consumption over 24 hours was measured during theCalculation of relative expression levels. Threshold cy-
study period on a group basis. The mean food intakecles (Ct) were defined as the number of PCR cycles at
per mouse of the NP group was 3.0  0.1 g/24 h. Foodwhich the fluorescent signal reached a fixed threshold
consumption did not differ significantly during the exper-signal. PCR efficiencies for both primers sets were
imental period in any of the groups (data not shown).95%. Relative expression levels were determined ac-
Also, no changes in blood glucose or insulin levels werecording to the comparative method [27].
seen in any group at any time point (data not shown).
Quantification
Kidney weight and GH/IGF system expressionAutoradiographs of WLBs were scanned using a laser
At the end of the experimental periods, kidney weightsdensitometer (Shimadzu model CS 90001 PC; Shimadzu
were determined. Kidney weights in the NP group wereEurope GmbH, Duisburg, Germany) and the relative
227  3 mg and 221  3 mg at d2 and d7, respectively.densities of the bands were expressed in pixels. Northern
At d7, the wet-weight of the kidneys was significantlyblots were scanned on a Phosphor Imager (Molecular
increased in the HP group to 245  2 mg (P 	 0.001)Dynamics, Sunnyvale, CA, USA) and quantified using
and in the HP/GHRA group to 242  4 mg (P 	 0.001;ImageQuant software. All measured mRNA results were
expressed relative to GAPDH mRNA levels. Fig. 1). Related to body weight, both HP and HP/GHRA
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Fig. 2. Kidney IGF-I (g/L; A) and IGFBP-4
(artificial values; B ) levels of mice receiving
a normal protein fodder (), high-protein fod-
der ( ) and high-protein fodder  GHRA
B2036-PEG ( ) for 2 and 7 days. Values are
means  SEM (N  8). **P  0.01, ***P 
0.002, statistical significance level between the
indicated group and the respective control.
#P  0.04, ##P  0.01, statistical significance
level between the high-protein/GHRA group
and the high-protein group.
administration significantly increased the weight of the mRNA levels both at d2 and d7 (P  0.008 and P 	
0.03, respectively, and when compared to the HP group;kidneys at d2 and d7: P  0.005 and P 	 0.001 at d2
Fig. 3B). In the HP group, IGFBP-4 mRNA levels sig-and P 	 0.001 and P 	 0.001 at d7, for HP and HP/
nificantly decreased at d2 and d7 (P 	 0.001 and P 	GHRA, respectively.
0.04, respectively). At d2, GHRA administration did notCompared to the NP group, renal IGF-I levels were
have an additional effect. However, at d7, GHRA signifi-significantly increased in the HP groups at d2 (P  0.01)
cantly increased hepatic IGFBP-4 mRNA levels (P and d7 (P  0.002). GHRA administration did not fur-
0.001; Fig. 3B). IGFBP-5 mRNA levels were not modifiedther modify renal IGF-I levels (Fig. 2A).
by HP and/or GHRA administration (results not shown).Using WLB, four distinct IGFBP bands were obtained.
Renal IGFBP-6, IGF-I, IGF-II and IGF-I receptorA double band at 38-42 kD representing IGFBP-3, a sin-
mRNA levels were not detectable in any of the groups.gle 30 kD band (IGFBP-1 and -2) and a 24 kD band
identified as IGFBP-4. Renal 30 kD IGFBPs (IGFBP-1
Circulating IGF-I and IGFBPs, liver weight and liverand -2) and IGFBP-3 levels were unchanged in all groups
GH/IGF system mRNA expression(results not shown), whereas renal IGFBP-4 levels were
significantly decreased in the HP group at d2 (P  0.01) At the end of the study periods, circulatory IGF-I
levels were determined in all groups. In the NP group,but not at d7 (Fig. 2B). Compared to the HP group,
GHRA administration increased IGFBP-4 levels both circulatory IGF-I levels were 236  24 L/L at d2 and
226  12 L/L at d7 and remained unchanged in theat d2 and d7 (P 0.01 and P 0.04, respectively; Fig. 2B).
Renal GHBP mRNA levels were significantly reduced HP and HP/GHRA groups (results not shown). IGFBP-3
levels were increased in the HP group at d2 (P  0.02)in the HP group at d2 (P  0.005) when compared to the
NP group. At d7 both GHR and GHBP mRNA levels but remained unchanged at d7. Circulatory 30 kD IGFBPs
(IGFBP-1 and -2) and IGFBP-4 levels were unchangedwere significantly reduced in the HP group (P 	 0.003
and P  0.004, respectively). GHRA administration for in all groups (results not shown).
Liver weight in the NP group was 968  78 mg. Liver7 days significantly increased GHR and GHBP mRNA
levels (P  0.01 and P  0.03, respectively; Fig. 3A). weights were not significantly modified in any of the
treatment groups (data not shown).Renal IGF-I mRNA levels were not significantly al-
tered in any of the groups (results not shown). IGFBP-1 Compared to the NP group, hepatic GHR and GHBP
mRNA levels were significantly reduced in the HP groupmRNA levels decreased in the HP/GHRA group both
at d2 and d7 (P  0.007 and P 	 0.001, respectively), both at d2 (P 	 0.001) and d7 (P 	 0.001). Also in the
HP/GHRA group, GHR and GHBP mRNA levels werewhereas the levels in the HP group remained unchanged
(results not shown). In the HP and HP/GHRA groups significantly reduced at d2 (both P 	 0.001). However,
GHRA administration for 7 days resulted in significantlyIGFBP-2 mRNA levels were significantly decreased
after 7 days (P  0.02) without an additional effect of increased GHR and GHBP mRNA levels (P 	 0.001)
(Fig. 4A).GHRA administration (results not shown). HP feeding
did not change renal IGFBP-3 mRNA levels. In contrast, Hepatic IGF-I mRNA levels were significantly re-
duced in the HP group both at d2 and d7 (P 	 0.001GHRA administration significantly reduced IGFBP-3
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Fig. 3. (A ) Renal GH-receptor (GHR) and
GH-binding protein (GHBP) mRNA levels
in adult mice fed for 2 and 7 days with normal-
protein fodder (), high-protein fodder ( ),
and high-protein fodder  GHRA B2036-
PEG ( ). Values are based on quantitations
of Northern blots, compensated for RNA
loading differences. Values are means SEM
(N  8). *P 	 0.007, **P 	 0.003; statistical
significance level between the high-protein
group and the normal-protein group. #P 
0.03, ##P  0.01; statistical significance level
between the high-protein group and the high-
protein/GHRA group. (B ) Renal IGFBP-3
and -4 mRNA levels in adult mice fed for 2
and 7 days with normal-protein fodder (),
high-protein fodder ( ), and high-protein
fodderGHRA B2036-PEG ( ). Values are
based on quantitations of Northern blots,
compensated for RNA loading differences.
Values are means  SEM (N  8). *P 
0.04, **P 	 0.001; statistical significance level
between the high-protein group and the nor-
mal-protein group. #P 	 0.03, ##P  0.008,
##P  0.001; statistical significance level be-
tween the high-protein group and the high-
protein/GHRA group.
and P 0.008, respectively). However, GHRA adminis- (P 0.001; Fig. 4B). IGFBP-4 mRNA levels significantly
tration for 7 days significantly increased the IGF-I increased at d2 in both the HP and the HP/GHRA group
mRNA level to NP values (P  0.02; Fig. 4B). (P  0.01 and P  0.03, respectively). However, at d7,
Acid labile subunit (ALS) mRNA levels also were strongly increased hepatic IGFBP-4 mRNA levels (to
significantly reduced in the HP group both at d2 and d7 2.05  0.04; P 	 0.001) only could be observed in the
(P	 0.001) and increased to NP levels in the HP/GHRA HP/GHRA group (results not shown).
group at d7 (Fig. 4B) Hepatic IGFBP-5 and -6, IGF-II and IGF-I receptor
Compared to the NP group, hepatic IGFBP-1 and -2 mRNA levels were not detectable in any of the groups.
mRNA levels had a tendency to decrease after 2 days
To further validate the GH-independence of the HP-of HP feeding, however, significance for IGFBP-2 was
induced renal enlargement, we repeated the experimentonly reached in the HP/GHRA group (P  0.001). In
and included a fourth group consisting of an eightfoldcontrast, at d7, IGFBP-1 and -2 mRNA levels were com-
increased dose of the antagonist (HP/8GHRA group;parable in all groups (results not shown). IGFBP-3
Table 1). Circulating IGF-I and hepatic IGF-I mRNAmRNA levels were significantly reduced in the HP group
were significantly lowered in this HP/8GHRA groupat d2 (P 0.001), without an additional effect of GHRA
(both P 	 0.001). For body weight, kidney weight, renaladministration. In contrast, at d7, IGFBP-3 mRNA levels
were increased to control values in the HP/GHRA group IGF-I and IGF-I mRNA and IGFBP-3, no significant
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Fig. 4. (A ) Liver growth hormone receptor
(GHR) and GH-binding protein (GHBP)
mRNA levels in adult mice fed for 2 and 7
days with normal-protein fodder (), high-
protein fodder ( ), and high-protein fodder
GHRA B2036-PEG ( ). Values are based on
quantitations of Northern blots, compensated
for RNA loading differences. Values are as
means SEM (N  8). *P 0.001, statistical
significance level between the high-protein
group and the normal-protein group. #P 
0.001, statistical significance level between the
high-protein/GHRA group and the high-pro-
tein group. (B ) Liver IGF-I, acid labile sub-
unit (ALS) and IGFBP-3 mRNA levels in
adult mice fed for 2 and 7 days with normal-
protein fodder (), high-protein fodder ( ),
and high-protein fodder  GHRA B2036-
PEG ( ). Values are based on quantitations
of Northern blots, compensated for RNA
loading differences. Values are means SEM
(N  8). *P  0.008, **P  0.001, statistical
significance level between the high-protein
group and the normal-protein group. #P 	
0.02, ##P 	 0.001, statistical significance level
between the high-protein/GHRA group and
the high-protein group.
Table 1. Repeated experiment with a fourth group
Normal protein High protein HP/GHRA HP/8GHRA
Body weight g 19.10.5 18.70.3 18.50.4 18.40.3
Kidney weight mg 2174 2412c 2463c 2475c
Kidney IGF-I ng/g 1687 2038b 1975b 1952b
Kidney IGF-I mRNA arbitrary units 10010 858 868 8014
Circulating IGF-I 24818 25213 2367 1785b,d,e
Liver IGF-I mRNA arbitrary units 1008 15325 14310b 796a,e
Circulating IGFBP-3 arbitrary units 137841 130090 1514154 134587
Body weight, kidneys weight, kidney insulin-like growth factor-I (IGF-I), kidney IGF-I mRNA, circulating IGF-I, liver IGF-I mRNA and circulating insulin-like
growth factor binding protein (IGFBP-3) levels in adult mice fed for 7 days with normal-protein fodder, high-protein fodder, high-protein fodder  1.25 mg/kg/day
growth hormone receptor antagonist B2036-PEG (HP/GHRA), and high-protein fodder  10 mg/kg/day GHRA B2036-PEG (HP/8GHRA) mRNA values are
based on real-time quantitative PCRs, compensated for differences in starting amount. Values are means  SEM (N  8).
a P 	 0.05, b P 	 0.01, c P 	 0.001, statistical significance level between the indicated group and the normal-protein group
d P  0.001, statistical significance level between the high-protein group and the HP/GHRA group
e P  0.001; statistical significance level between the HP/GHRA group and the HP/8  GHRA group
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change could be observed between the HP/GHRA and renal IGF-I increased to supranormal levels irrespective
of the presence of the GHRA. In the liver, HP feedingHP/8GHRA group (Table 1).
decreased ALS and IGFBP-3 mRNA levels. In contrast,
GHRA addition increased ALS and IGFBP-3 mRNA
DISCUSSION
levels. Low protein feeding for 7 days did not affect
The major new finding of this study is that the well- ALS or IGFBP-3 mRNA levels [38]. In the kidney, the
known HP-induced renal enlargement is not GH-depen- observed increased IGF-I levels likely created an in-
dent. crease in IGF-I bioavailability that may have contributed
The relationship between GH–IGF-I, food intake and to the observed increase in renal weight. In the liver,
renal growth has attracted much attention. Short-term unchanged IGF-I and increased IGFBP mRNA levels
fasting and long-term starvation both reduced circulatory caused a decrease in IGF-I bioavailability that did not
IGF-I levels [28, 29] and renal mass [30], and accordingly modify liver weight.
it was suggested that IGF-I (circulating and/or renal) Growth hormone and IGF-I also have been implicated
contributed to the renal mass increase. Also, in fasted in other pathophysiological conditions with increased
GH-deficient rats, renal IGF-I levels were reduced renal growth, such as diabetes and CRG following uni-
whereas renal IGFBP-1 levels were increased [31]. Ad- nephrectomy. Here, GHRA administration at a concen-
ministration of high-dose GH to these animals restored tration also used in this study, inhibited the renal weight
hepatic IGF-I mRNA abundance, however, did not pro- increase and glomerular hypertrophy and reduced renal
duce a normal increase of the circulatory IGF-I concen- IGF-I [4, 14]. This suggests that in these pathological
tration [32]. In humans, protein-energy malnutrition is conditions renal GH-action is a prerequisite for the renal
accompanied by a high circulatory concentration of GH effects. In contrast, GHRA administration did not abol-
that also fails to maintain IGF-I in the normal range ish HP-induced renal enlargement as shown in this study.
[32]. Increased dietary protein feeding demonstrated the The HP model may be important for understanding
opposite effect, that is, increased renal IGF-I levels with the role of IGF-I in physiological processes, and GHRA
HP-induced renal growth [11]. In rats with partial ne- additionally may provide insight in the effects of blocking
phrectomy, HP-diets even further increased renal IGF-I locally produced renal IGF-I. In our study, renal IGF-I
[17, 33, 34]. However, dietary protein content did not was significantly elevated, irrespective of a GHR block-
influence renal hypertrophy and renal IGF-I levels in ade. We can only speculate about the mechanism that
GH-deficient dwarf rats [12, 34]. This suggested a GH- leads to the increased renal IGF-I levels. It may be that
dependence of the HP-induced renal growth. In contrast, HP directly increased renal transcription of the IGF-I
however, other studies using GH-deficient animals have gene, although on our Northern blots, IGF-I mRNA
described HP-induced renal growth and renal IGF-I, levels were not detectable in any of the groups. However,
suggesting GH-independence [7, 35]. Chin and Bondy, using in situ hybridization in GH-defi-
Our study directly blocked the effects of GH at the cient rats, demonstrated increased IGF-I mRNA levels
receptor level, and demonstrated a HP-induced renal in the medullary thick ascending limb in response to HP
growth independent of the GH-status. The GHRA was feeding [7]. Alternatively, post-transcriptional regulation
used at a concentration that did not significantly modify may underlay the increased IGF-I levels. In this context,
circulatory IGF-I [4, 14, 16, 36]. However, we had all Straus and Takemoto studied dietary protein restriction
signs of a GHR blockade at the hepatic and renal level, and demonstrated a greater decrease in the hepatic 7.5
such as increased hepatic and renal IGFBP-4 mRNA kb IGF-I mRNA than the other IGF-I mRNAs [39].
and protein levels, and GHR/GHBP mRNA levels [36]. Finally, it also may be that the changed IGFBP profiles
In the rat, alternative splicing of a single transcript results attracted IGF-I to the kidney. Especially the role of
in a distinct GHR and GHBP mRNAs [37]. The observed IGFBP-1 deserves further attention, as it is implicated
increased GHR mRNA levels likely represented a com- in mechanisms resulting in increased renal weight. In a
pensatory up-regulation of the GHR gene expression in recent study by Doublier et al, using IGFBP-1 transgenic
response to the functional blockade of the GHR by the mice, renal glomerular hypertrophy was observed al-
GHRA. Furthermore, GHRA at this concentration has though with unaltered renal weight [40]. In another re-
been proven to block GH-effects on kidneys [4, 14, 16]. cent study by van Buul-Offers et al, IGFBP-1 was admin-
This was further verified in a second experiment where a istered to Snell dwarf mice and an increased renal weight
high dose of the GHRA was used that significantly low- was observed, whereas the weights of most other organs
ered circulatory IGF-I. Also, at this dose a HP-induced and body weights were inhibited [41]. In our study, he-
renal growth could be demonstrated indicating its GH- patic IGFBP-1 mRNA levels did not change in any of
independence. the groups. However, the unmodified 30 kD band in the
Renal IGFBP-1 and IGFBP-3 mRNAs were reduced WLB consists of multiple IGFBPs (IGFBP-1, -2 and/or
-5). Therefore, we cannot exclude increased circulatorywhen GHRA was added to the HP group. In contrast,
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mone and growth hormone releasing factor but not in those ex-IGFBP-1 levels, as antisera detecting rodent IGFBP-1
pressing insulin like growth factor-1. Am J Pathol 131:398–403,
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